Ability to metabolize tamoxifen affects breast cancer outcomes

For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug’s effectiveness and the likelihood breast cancer will recur. A new study provides evidence that genetic differences in the enzyme CYP2D6 play a key role in how well tamoxifen works.

Read the whole article on Science Daily

More from Science Daily